Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.43 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.43 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.43 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | NAAA | Q02083 | 1/20 | 0.41 |
| ▸ | PDE4A | P27815 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24760208 | 0.89 | L3MBTL1 (0.48) | L3MBTL1MAPTSMN1; SMN2LMNAMEN1 | |
| SCHEMBL18430370 | 0.87 | L3MBTL1 (0.45) | L3MBTL1MAPTSMN1; SMN2LMNAMEN1 | |
| SCHEMBL24760348 | 0.86 | CTSK (0.46) | LMNAMEN1KMT2APRSS1TPSAB1 | |
| SCHEMBL24760365 | 0.84 | KCNA5 (0.47) | L3MBTL1MAPTSMN1; SMN2LMNACTSK | |
| SCHEMBL19001575 | 0.83 | CTSK (0.44) | L3MBTL1MAPTSMN1; SMN2LMNAMEN1 | |
| SCHEMBL17448273 | 0.83 | CTSK (0.49) | L3MBTL1MAPTSMN1; SMN2LMNAMEN1 | |
| SCHEMBL15499765 | 0.83 | ALDH1A1 (0.56) | L3MBTL1MAPTSMN1; SMN2LMNAMEN1 | |
| SCHEMBL13684290 | 0.83 | NAAA (0.51) | L3MBTL1MAPTSMN1; SMN2LMNAPRSS1 | |
| SCHEMBL25062103 | 0.83 | TOP2A (0.49) | LMNAMEN1KMT2APRSS1TPSAB1 | |
| SCHEMBL22388944 | 0.83 | LMNA (0.45) | L3MBTL1MAPTSMN1; SMN2LMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022262789-A1 | ANTITUMOR COMPOUND AND USE THEREOF | 明慧医药（杭州）有限公司 | 2022-12-22 | — | — | WO | disclosed |
| US-20200276261-A1 | A CONJUGATE OF A TUBULYSIN ANALOG WITH BRANCHED LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2020-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200276261-A1 | A CONJUGATE OF A TUBULYSIN ANALOG WITH BRANCHED LINKERS | TEKT1, TEK, BTN3A1 | L3MBTL1 1087/4885MAPT 2764/4885SMN1; SMN2 3844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.